Monocyte dipeptidyl peptidase 4 activity is associated with urinary albumin excretion in type 2 diabetes Authors: Hideyuki Okuma, Takahiro Tsutsumi, Kyoichiro Tsuchiya Published: 2026 ABSTRACT ABSTRACTIntroductionPrevious reports have suggested the involvement of pro‐inflammatory genes in monocytes and dipeptidyl peptidase 4 (DPP4) in the pathogenesis of diabetic kidney disease (DKD); however, whether DPP4 in monocytes is associated with renal parameters remains unclear.Materials and MethodsWe conducted a cross‐sectional study of 64 patients with type 2 diabetes mellitus (T2DM) not taking incretin‐based medications and 50 healthy controls not taking any medication and without cardiovascular risk factors. Peripheral blood monocytes were isolated from the participants, cultured, and stimulated with vehicle or lipopolysaccharide (LPS). After cell harvesting, data regarding DPP4 and pro‐inflammatory genes in monocytes were investigated by quantitative real‐time polymerase chain reaction and DPP4 activity assay. We evaluated renal parameters based on the urinary albumin‐to‐creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR).Results DPP4 gene expression and DPP4 activity in unstimulated monocytes were elevated in patients with T2DM compared with healthy controls. In the T2DM group, DPP4 gene expression in LPS‐stimulated monocytes, but not in unstimulated monocytes, was significantly and positively correlated with UACR and the expression of LPS‐stimulated pro‐inflammatory genes, but not with eGFR. Furthermore, DPP4 activity in both unstimulated and LPS‐stimulated monocytes in the T2DM group was significantly and positively correlated with UACR and the expression of LPS‐stimulated pro‐inflammatory genes but not with eGFR.ConclusionsThe findings suggested that monocyte DPP4 activity is associated with urinary albumin excretion in patients with T2DM, with or without LPS stimulation. Monocytes may serve as a cellular link between DPP4 and DKD.Keywords: diabetic kidney disease, dipeptidyl peptidase 4, monocyte INTRODUCTION Chronic kidney disease (CKD) is defined by reduced estimated glomerular filtration rate (eGFR) and/or increased albuminuria 1 , 2 . Diabetic kidney disease (DKD), affecting approximately 40% of patients with diabetes, represents a major complication 3 . Its pathogenesis remains incompletely understood, and reliable biomarkers are limited, highlighting the need to clarify underlying mechanisms to develop effective therapeutic strategies 4 . DKD severity is associated with chronic inflammation in addition to glycemic control, diabetes duration, and hypertension 5 , 6 , 7 , 8 . Circulating markers such as high‐sensitivity C‐reactive protein (hsCRP) and advanced glycation end products (AGEs) have been identified as predictors of DKD severity 9 , 10 , 11 , 12 , 13 , 14 . Moreover, monocyte/macrophage accumulation contributes to CKD pathogenesis, and peripheral blood monocytes and peripheral blood mononuclear cells (PBMCs) in patients with DKD exhibit increased expression of inflammation‐related genes 15 , 16 , 17 , 18 . In recent years, blood dipeptidyl peptidase‐4 (DPP4) activity and soluble DPP4 concentration have been reported to be biomarkers of DKD in patients with diabetes 12 , 19 , 20 , 21 . DPP4 reportedly induces DKD by stimulating the inflammatory pathway in renal tubular cells 22 . These reports suggest that inflammation and DPP4 are related to DKD in patients with diabetes; however, the systemic and comprehensive inflammatory mechanisms by which DPP4 contributes to DKD development remain unclear. In this study, we focused on DPP4 expression in monocytes as a link between inflammation and DKD. Previous research has reported that inflammation and DPP4 in the monocyte/macrophage system positively regulate each other 23 , 24 . We aimed to elucidate the systemic mechanism by which DPP4 contributes to the pathogenesis of DKD through examining whether the characteristics of DPP4 in peripheral blood monocytes of patients with type 2 diabetes mellitus (T2DM) relate to renal parameters. MATERIALS AND METHODS Study design and participants In this cross‐sectional study, following the recruitment process illustrated in Figure 1, 64 patients with T2DM who were not receiving incretin‐based therapies at the University of Yamanashi Hospital, and 50 adult volunteers who were not taking any medications, had no history of diabetes, hypertension, dyslipidemia, or atherosclerotic diseases (including stroke, ischemic heart disease, and peripheral arterial disease), and underwent health checkups at Isawa Onsen Hospital, were included in the final analysis. At the initial stage of recruitment, written informed consent was obtained from 68 patients with T2DM and 52 adult volunteers in the healthy control group. Among the candidates, the T2DM study population was reduced to 65 based on the exclusion criteria: (1) severe renal impairment (patients receiving renal replacement therapy or with an eGFR <15 mL/min/1.73 m2), (2) pregnancy, and (3) acute kidney injury defined according to the Kidney Disease Improving Global Outcomes (KDIGO) 25 . Blood samples, including the collection of peripheral blood monocytes, were obtained from these 65 patients and the 52 healthy controls. Subsequently, one patient with T2DM and two healthy controls were excluded due to withdrawal of consent, and the remaining participants were included in the final analysis. The study was approved by the certified review boards of the University of Yamanashi (#1668) and Isawa Hot Spring Hospital (#2018‐003). Written informed consent was obtained from all participants. Flowchart showing the participant selection process. The process of selecting study participants is shown. T2DM, type 2 diabetes mellitus. Clinical data collection Data on demographics (including age, sex, the duration of DM, smoking status, and body mass index [BMI]), complications of DM (such as diabetic neuropathy, retinopathy, DKD, and atherosclerotic diseases), physiological measurements (covering systolic and diastolic blood pressure [SBP and DBP] and mean intima‐media thickness [IMT] measured by carotid ultrasound), laboratory test outcomes, analysis using monocytes, and prescribed medications were collected. Carotid ultrasound examinations were performed only in patients with T2DM. As part of their insurance‐covered medical care, patients with T2DM had 11 parameters measured including fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), C‐peptide index, triglycerides (TG), high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol (LDL‐C), aspartate transaminase (AST), alanine transaminase (ALT), uric acid (UA), urinary albumin‐to‐creatinine ratio (UACR), and eGFR. Healthy controls had the same parameters measured as part of their health checkup, excluding C‐peptide index and UACR. Furthermore, at the same time, we collected additional blood samples to measure serum hsCRP and AGEs, plasma DPP4 activity, and to isolate monocytes. Blood samples were collected in the morning after fasting for at least 12 h. The levels of HbA1c were measured using latex agglutination, and plasma glucose levels were measured using a glucose oxidase method. Endogenous insulin secretion capacity was evaluated using the C‐peptide index, calculated as the fasting C‐peptide (ng/mL) divided by fasting blood glucose (mg/dL) × 100. The eGFR was calculated using the CKD‐EPI equation modified with a Japanese coefficient 26 . The concentrations of urinary albumin and creatinine were measured through turbidimetric immunoassay and enzymatic methods, respectively, and the UACR (mg/gCr) was calculated to evaluate albuminuria in spot urine samples. Serum hsCRP levels were quantified using the immunoturbidimetric CRP‐Latex assay (Kamiya Biomedical Co., WA, USA), according to the manufacturer's protocol. Serum AGE levels were measured using the OxiSelectTM AGEs ELISA Kit (Cell Biolabs Inc., San Diego, CA, USA), according to the manufacturer's protocol. Plasma DPP4 activity was determined based on the rate of cleavage of 7‐amino‐4‐methylcoumarin (AMC) from the synthetic substrate H‐glycyl‐prolyl‐AMC (H‐Gly‐Pro‐AMC; Biovision, San Francisco, CA, USA) and was expressed as nmol of AMC cleaved per min per mL (nmol/min/mL). Measurements of serum hsCRP, AGEs, and plasma DPP4 activity were performed in duplicate, with any discrepancies outside of three standard deviations prompting reanalysis. DKD was defined as diabetes with a UACR of ≥30 mg/g and/or an eGFR of <60 mL/min/1.73 m2 in the absence of signs or symptoms of other primary causes of kidney damage according to the KDIGO guidelines. In subgroup analyses of patients with T2DM, participants were classified into four categories based on albuminuria and eGFR: normoalbuminuria (UACR <30 mg/g), microalbuminuria (UACR of 30 to <300 mg/g), macroalbuminuria (UACR ≥300 mg/g), and moderately reduced renal function (eGFR of 30 to <60 mL/min/1.73 m2). Monocyte isolation and cell culture Approximately 25 mL of an early‐morning fasting anticoagulated blood sample (K‐EDTA) was diluted with an equal volume of lymphocyte separation solution (Nakalai Tesque, Kyoto, Japan) and carefully layered into a 50 mL Falcon tube (Costar, Corning, NY, USA). Samples were centrifuged at 400 × g in a swing‐out rotor for 30 min at 22°C, and the PBMC layer was harvested using a pipette. PBMCs were repeatedly washed with Dulbecco's Modified Eagle Medium (DMEM) (Thermo Fisher Scientific Inc., Waltham, MA, USA) containing 1% penicillin/streptomycin (P/S) and 10% fetal bovine serum (FBS). The PBMCs were cultured on collagen‐coated multi‐well plates in DMEM with 1% P/S containing 10% FBS for 2 h in an incubator. Next, the PBMCs were washed with phosphate‐buffered saline (PBS) to remove lymphocytes 27 , 28 . Monocytes were then replaced with DMEM containing 0.25% bovine serum albumin (BSA) and starved for 2 h in an incubator. Monocyte purity was verified using a FACSCelesta (Becton, Dickinson and Company, NJ, USA) and a phycoerythrin (PE)‐conjugated anti‐human CD14 Antibody (BioLegend, CA, USA) in our previous report 29 . Cultured monocytes were pretreated in 12‐well plates with vehicle or 10 μM vildagliptin for 2 h, followed by stimulation with vehicle or 10 ng/mL lipopolysaccharide (LPS) for 4 h. For the analysis of culture supernatants, monocytes were stimulated with either vehicle or 10 ng/mL LPS for 24 h instead of 4 h. The downstream assays including RNA extraction and DPP4 activity assay were immediately performed on freshly isolated monocytes. The levels of TNF‐α in the culture supernatants were determined using the Quantikine Human TNF‐α ELISA Kit (R&D Systems, MN, USA). Unstimulated samples of monocytes and culture supernatants were available from all participants, whereas samples after stimulation with LPS alone or combined with vildagliptin were obtained from 48 controls and 50 patients with T2DM. Quantitative real‐time polymerase chain reaction analysis Total RNA from cultured human monocytes was isolated using TRIzol (Thermo Fisher Scientific Inc.), as previously described 30 . The RNA was reverse transcribed using Random Primer (Thermo Fisher Scientific Inc.) and ReverTra Ace (Toyobo Co., Ltd., Osaka, Japan). Quantitative real‐time polymerase chain reaction (qRT‐PCR) was conducted using ViiA™ 7 Real‐Time PCR Systems with Fast SYBR Green Master Mix Reagent (Thermo Fisher Scientific Inc.). Primer sequences are available upon request. Data were normalized to the actin beta gene expression levels and analyzed using the comparative threshold cycle and relative quantification method. The expression levels of DPP4 gene and pro‐inflammatory genes, including interleukin 1 beta (IL‐1β), interleukin‐6 (IL‐6), monocyte chemotactic protein‐1 (MCP‐1), and tumor necrosis factor‐alpha (TNFA), before and after LPS stimulation were analyzed. Monocyte DPP4 activity assay DPP4 activity in monocytes was measured using a DPP4 fluorometric activity assay kit (Abcam kit #ab204722, Toronto, ON, Canada), according to the manufacturer's protocol. Cultured human monocytes were grown to a density of 2 × 106 cells per well and subsequently treated in medium containing charcoal‐stripped 10% FBS with either vehicle or 10 ng/mL LPS for 4 h. Cells were then harvested and assayed according to the manufacturer's protocol. Statistical analyses Statistical analyses were performed using Prism 9 (GraphPad Software Inc., San Diego, CA, USA). Normally distributed variables were analyzed by t‐test, non‐normal variables by Mann–Whitney U or Wilcoxon tests, categorical variables by chi‐square or Fisher's exact tests, and correlations by Spearman's rank coefficient. In the multivariate model of linear regression analysis, we adjusted for the following variables using a stepwise procedure in Model 1: age, female sex, duration of DM, current smoking status, BMI, complications of DM excluding DKD, physiological measurements, laboratory parameters, data analyzed using unstimulated monocytes, and medications. In addition to the variables selected in Model 1, Model 2 included baseline eGFR and HbA1c as forced entry variables, and Model 3 included BMI and SBP as forced entry variables. Continuous variables that were not normally distributed were log‐transformed using the natural logarithm before being entered into these models. Statistical significance was established when the P‐value was <0.05. RESULTS We included 64 patients with T2DM and 50 healthy control participants in this study. The characteristics of all participants are shown in Table 1. BMI, SBP, FPG, HbA1c, TG, ALT, UA, hsCRP, AGEs, and plasma DPP4 activity were significantly elevated in the T2DM group. LPS‐stimulated expression of pro‐inflammatory genes in monocytes and LPS‐stimulated TNF‐α production in culture supernatants were significantly higher in the T2DM group than in the healthy control group. Table 1Baseline characteristics of all participantsOverall (n = 114)T2DM (n = 64)Healthy controls (n = 50) P‐valueClinical characteristics at baselineAge (year)64.0 ± 12.861.8 ± 8.490.288Female sex, n (%)29 (45)22 (44)1.000Duration of DM (years)13 (12–15)N/ACurrent Smoker (n, %)31 (48)20 (40)0.449BMI (kg/m2)25.4 ± 5.122.5 ± 2.9<0.001Complications of DM (n, %)Neuropathy37 (58)N/ARetinopathy26 (41)N/ADKD30 (47)N/AAtherosclerotic diseases12 (19)N/AClassification based on eGFR or UACReGFR ≥ 6048 (75)45 (90)0.05230 ≤ eGFR < 6016 (25)5 (10)eGFR < 300 (0)0 (0)1.000UACR < 3035 (55)N/A30 ≤ UACR < 30016 (25)N/AUACR ≥ 30013 (20)N/APhysiological testingSBP (mmHg)132 ± 17117 ± 10<0.001DBP (mmHg)72 ± 1173 ± 80.541Mean IMT (mm)1.0 (0.7–1.3)N/ALaboratory parametersFPG (mg/dL)137 (112–185)96 (90–103)<0.001HbA1c (%)8.5 (7.7–10.4)5.6 (5.4–5.7)<0.001C‐peptide index1.13 (0.92–1.72)N/ATG (mg/dL)119 (90–174)75 (55–106)<0.001HDL‐C (mg/dL)45 (40–54)61 (51–72)<0.001LDL‐C (mg/dL)120 (99–135)121 (101–135)0.826AST (IU/L)21 (18–31)21 (17–23)0.057ALT (IU/L)26 (19–37)17 (13–24)<0.001UA (mg/dL)5.6 (4.6–7.7)4.7 (3.5–6.4)0.005UACR (mg/gCr)25.3 (12.4–110.4)N/AeGFR (mL/min/1.73 m2)68.7 ± 20.871.4 ± 9.660.406hsCRP (mg/L)6.2 (4.3–7.7)1.7 (1.2–2.7)<0.001AGEs (μg/mL)176.0 (146.8–220.6)86.2 (73.3–99.0)<0.001Plasma DPP4 activity (nmol/min/mL)12.10 (9.76–15.02)6.83 (5.43–8.72)<0.001Data regarding monocytesUnstimulated IL‐1β gene expression † 4.87 (4.66–5.10)4.87 (4.61–5.14)0.889LPS‐stimulated IL‐1β gene expression ‡ 20.05 (10.28–55.14)7.40 (5.47–11.30)<0.001Unstimulated IL‐6 gene expression † 5.84 (5.57–6.19)6.00 (5.60–6.24)0.291LPS‐stimulated IL‐6 gene expression ‡ 33.38 (11.31–80.77)9.25 (6.31–15.38)<0.001Unstimulated MCP‐1 gene expression † 8.32 (7.80–8.93)8.41 (7.77–8.90)0.822LPS‐stimulated MCP‐1 gene expression ‡ 25.89 (11.31–62.31)11.68 (7.40–22.40)0.001Unstimulated TNFA gene expression † 3.37 (3.13–3.56)3.25 (2.51–4.22)0.880LPS‐stimulated TNFA gene expression ‡ 25.15 (13.52–61.56)13.94 (8.09–21.06)<0.001Unstimulated TNF‐α levels in culture supernatants (pg/mL) † 9.73 (5.43–16.21)10.47 (9.98–11.39)0.177LPS‐stimulated TNF‐α levels in culture supernatants (pg/mL) ‡ 100.21 (26.27–153.38)43.92 (23.83–72.66)<0.001Medications (n, %)Insulin18 (28)0 (0)Sulfonylureas2 (3)0 (0)Glinides5 (8)0 (0)Metformins36 (56)0 (0)TZDs4 (6)0 (0)Alpha‐GIs3 (5)0 (0)SGLT2 inhibitors42 (66)0 (0)ARBs31 (48)0 (0)CCBs20 (31)0 (0)Diuretics3 (5)0 (0)Statins40 (63)0 (0)Fibrates22 (34)0 (0)UA lowering agents8 (13)0 (0)Anti‐platelet agents14 (22)0 (0)Data are expressed as the mean ± standard deviation, median (interquartile range), or number (%). P‐values were calculated for differences in percentages (chi‐square test), means (t‐test), or medians (Mann–Whitney U test). DKD was defined as UACR ≥ 30 mg/gCr and/or eGFR < 60 mL/min/1.73 m2. AGEs, advanced glycation end products; ALT, alanine transaminase; ARBs, angiotensin receptor blockers; AST, aspartate transaminase; BMI, body mass index; CCB, calcium channel blocker; DBP, diastolic blood pressure; DKD, diabetic kidney disease; DM, diabetes mellitus; DPP4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; FPG, fasting blood glucose; GIs, glycosidase inhibitors; HbA1c, hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; hsCRP, high‐sensitivity C‐reactive protein; IL‐1β, interleukin 1 beta; IL‐6, interleukin‐6; IMT, intima‐media thickness; LDL‐C, low‐density lipoprotein cholesterol; LPS, lipopolysaccharide; MCP‐1, monocyte chemotactic protein‐1; N/A, not available; SBP, systolic blood pressure; SGLT2, sodium‐glucose cotransporter 2; TG, triglycerides; TNFA, tumor necrosis factor‐alpha; TZDs, thiazolidinediones; T2DM, type 2 diabetes mellitus; UA, uric acid; UACR, urinary albumin‐to‐creatinine ratio. † Data analyzed using unstimulated monocytes. ‡ Data analyzed using LPS‐stimulated monocytes. Baseline characteristics of all participants Data are expressed as the mean ± standard deviation, median (interquartile range), or number (%). P‐values were calculated for differences in percentages (chi‐square test), means (t‐test), or medians (Mann–Whitney U test). DKD was defined as UACR ≥ 30 mg/gCr and/or eGFR < 60 mL/min/1.73 m2. AGEs, advanced glycation end products; ALT, alanine transaminase; ARBs, angiotensin receptor blockers; AST, aspartate transaminase; BMI, body mass index; CCB, calcium channel blocker; DBP, diastolic blood pressure; DKD, diabetic kidney disease; DM, diabetes mellitus; DPP4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; FPG, fasting blood glucose; GIs, glycosidase inhibitors; HbA1c, hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; hsCRP, high‐sensitivity C‐reactive protein; IL‐1β, interleukin 1 beta; IL‐6, interleukin‐6; IMT, intima‐media thickness; LDL‐C, low‐density lipoprotein cholesterol; LPS, lipopolysaccharide; MCP‐1, monocyte chemotactic protein‐1; N/A, not available; SBP, systolic blood pressure; SGLT2, sodium‐glucose cotransporter 2; TG, triglycerides; TNFA, tumor necrosis factor‐alpha; TZDs, thiazolidinediones; T2DM, type 2 diabetes mellitus; UA, uric acid; UACR, urinary albumin‐to‐creatinine ratio. Data analyzed using unstimulated monocytes. Data analyzed using LPS‐stimulated monocytes. Next, we used Spearman's rank correlation coefficient to identify factors related to plasma DPP4 activity, UACR, and eGFR in the T2DM group (Table S1). Plasma DPP4 activity showed a significant correlation with the duration of DM, BMI, UACR, hsCRP, AGEs, LPS‐stimulated expression of pro‐inflammatory genes in monocytes, and LPS‐stimulated TNF‐α production in culture supernatants; however, no significant correlation with eGFR was observed. While UACR showed a significant correlation with age, duration of DM, eGFR, hsCRP, AGEs, plasma DPP4 activity, LPS‐stimulated expression of pro‐inflammatory genes in monocytes, and LPS‐stimulated TNF‐α production in culture supernatants, eGFR showed a significant correlation with duration of DM, BMI, and UACR. On the other hand, plasma DPP4 activity in the healthy control group showed a significantly positive correlation with BMI and hsCRP (Table S2). Furthermore, we examined correlations of hsCRP, AGEs, and monocyte inflammatory markers in the T2DM group. Both hsCRP and AGEs were correlated with LPS‐stimulated TNFA gene expression, while neither was correlated with pro‐inflammatory gene expression in unstimulated monocytes (Table S3). The results in Table S1 suggest that plasma DPP4 activity and pro‐inflammatory gene expression in monocytes were related to UACR, prompting us to analyze DPP4 gene expression in monocytes. Unstimulated DPP4 gene expression in monocytes was significantly higher in the T2DM group than in the healthy control group (Figure S1a). Unstimulated DPP4 gene expression in the T2DM group showed no significant correlation with UACR, eGFR, plasma DPP4 activity, or LPS‐stimulated pro‐inflammatory gene expression (Table S4). Next, we analyzed LPS‐stimulated DPP4 gene expression in monocytes because previous studies demonstrated interrelationships between DPP4 in monocytes and inflammation 23 , 24 . DPP4 gene expression in monocytes of the T2DM group significantly increased after LPS stimulation, but this increase was not suppressed by the DPP4 inhibitor vildagliptin (Figure S1b). LPS‐stimulated DPP4 gene expression in the T2DM group showed a significantly positive correlation with UACR, hsCRP, AGEs, plasma DPP4 activity, and LPS‐stimulated pro‐inflammatory gene expression; however, no significant correlation with eGFR was noted (Table S4). On the other hand, unstimulated DPP4 gene expression in the healthy control group showed no correlation with plasma DPP4 activity or LPS‐stimulated pro‐inflammatory gene expression (Table S5). DPP4 gene expression in monocytes of the healthy control group significantly increased after LPS stimulation, but this increase was not suppressed by vildagliptin (Figure S2). LPS‐stimulated DPP4 gene expression in the healthy control group showed a significantly positive correlation with LPS‐stimulated pro‐inflammatory gene expression (Table S5). These results suggest that LPS‐stimulated DPP4 gene expression in monocytes of patients with T2DM is related to albuminuria. The function of DPP4 in each target organ depends not only on its expression level but also on its activity. Therefore, we analyzed DPP4 activity in peripheral blood monocytes. Unstimulated DPP4 activity in monocytes was significantly higher in the T2DM group than in the healthy control group (Figure 2a). Unstimulated DPP4 activity in monocytes from the T2DM group showed a significant correlation with UACR, hsCRP, AGEs, plasma DPP4 activity, LPS‐stimulated expression of pro‐inflammatory genes and DPP4 gene, and LPS‐stimulated TNF‐α levels in culture supernatants; however, no significant correlation with eGFR was noted (Table 2). Furthermore, we analyzed monocyte DPP4 activity after LPS stimulation. Monocyte DPP4 activity in the T2DM group significantly increased after LPS stimulation, and this increase was suppressed by vildagliptin (Figure 2b). LPS‐stimulated DPP4 activity in monocytes from the T2DM group showed a significant correlation with UACR, hsCRP, AGEs, plasma DPP4 activity, LPS‐stimulated expression of pro‐inflammatory genes and DPP4 gene, and LPS‐stimulated TNF‐α levels in culture supernatants; however, no correlation with eGFR was noted (Table 2). Unstimulated DPP4 activity in monocytes from the healthy control group showed a significantly positive correlation with LPS‐stimulated pro‐inflammatory gene expression (Table S6). Monocyte DPP4 activity in the healthy control group significantly increased after LPS stimulation, and this increase was suppressed by vildagliptin (Figure S3). LPS‐stimulated DPP4 activity in monocytes from the healthy control group showed a significantly positive correlation with LPS‐stimulated pro‐inflammatory gene expression (Table S6). These results suggested that monocyte DPP4 activity in patients with T2DM is related to albuminuria, with or without LPS stimulation. Analysis of DPP4 activity in cultured human monocytes. (a) Comparison of DPP4 activity in unstimulated monocytes between T2DM and healthy control groups (T2DM, n = 64; controls, n = 50). Data were compared using the Mann–Whitney U test. (b) The effects of LPS and vildagliptin on monocyte DPP4 activity. Cultured monocytes in the T2DM group were treated with LPS at a concentration of 10 ng/mL for 4 h, with or without a pretreatment of vildagliptin at a concentration of 10 μM for 2 h. The quantitative analysis of DPP4 activity (n = 50) is shown. Data were analyzed using the Wilcoxon signed‐rank test. All data are presented as box‐and‐whisker plots. The box represents the interquartile range, the horizontal line within the box indicates the median, and the whiskers represent the 10th and 90th percentiles. The median values are indicated at the bottom of each panel. DPP4, dipeptidyl peptidase‐4; LPS, lipopolysaccharide; T2DM, type 2 diabetes mellitus. *P < 0.05 and ***P < 0.001. Table 2Correlation analysis between DPP4 activity in cultured monocytes and other clinical characteristics in patients with T2DMT2DMUnstimulatedLPS‐stimulatedDPP4 activity (μU/well) † DPP4 activity (μU/well) ‡ ρ P‐valueρ P‐valueUACR0.801<0.0010.879<0.001eGFR−0.2380.089−0.2190.121hsCRP0.2830.0240.3650.009AGEs0.2970.0170.4310.002Plasma DPP4 activity0.3440.0050.4080.003LPS‐stimulated IL‐1β gene expression ‡ 0.2890.0420.4000.004LPS‐stimulated IL‐6 gene expression ‡ 0.3770.0070.463<0.001LPS‐stimulated MCP‐1 gene expression ‡ 0.3060.0310.3560.011LPS‐stimulated TNFA gene expression ‡ 0.462<0.0010.612<0.001LPS‐stimulated TNF‐α levels in culture supernatants ‡ 0.565<0.0010.602<0.001Unstimulated DPP4 gene expression † 0.1350.287−0.0590.682LPS‐stimulated DPP4 gene expression ‡ 0.681<0.0010.789<0.001Spearman's rank correlation analysis was performed. AGEs, advanced glycation end products; DPP4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; hsCRP, high‐sensitivity C‐reactive protein; IL‐1β, interleukin 1 beta; IL‐6, interleukin‐6; LPS, lipopolysaccharide; MCP‐1, monocyte chemotactic protein‐1; TNFA, tumor necrosis factor‐alpha; T2DM, type 2 diabetes mellitus; UACR, urinary albumin‐to‐creatinine ratio; ρ, Spearman's correlation coefficient. † Data analyzed using unstimulated monocytes. ‡ Data analyzed using LPS‐stimulated monocytes. Correlation analysis between DPP4 activity in cultured monocytes and other clinical characteristics in patients with T2DM Spearman's rank correlation analysis was performed. AGEs, advanced glycation end products; DPP4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; hsCRP, high‐sensitivity C‐reactive protein; IL‐1β, interleukin 1 beta; IL‐6, interleukin‐6; LPS, lipopolysaccharide; MCP‐1, monocyte chemotactic protein‐1; TNFA, tumor necrosis factor‐alpha; T2DM, type 2 diabetes mellitus; UACR, urinary albumin‐to‐creatinine ratio; ρ, Spearman's correlation coefficient. Data analyzed using unstimulated monocytes. Data analyzed using LPS‐stimulated monocytes. We examined whether the correlation between monocyte DPP4 activity and urinary albumin excretion was also present within subgroups stratified by albuminuria and eGFR. In all subgroups—normoalbuminuria, microalbuminuria, macroalbuminuria, and moderately reduced eGFR—monocyte DPP4 activity showed a significant positive correlation with UACR, with or without LPS stimulation, but not with eGFR (Table 3). These findings suggest that monocyte DPP4 activity may be associated with albuminuria, regardless of disease stage. Table 3Correlation analyses of monocyte DPP4 activity with UACR and eGFR within subgroups stratified by albuminuria and eGFR in patients with T2DMT2DMUnstimulatedLPS‐stimulatedDPP4 activity (μU/well) † DPP4 activity (μU/well) ‡ ρ P‐valueρ P‐valueNormoalbuminuria(n = 35)(n = 24)UACR0.704<0.0010.666<0.001eGFR−0.0420.813−0.1120.602Microalbuminuria(n = 16)(n = 14)UACR0.7020.0020.7300.003eGFR−0.0310.9090.2510.387Macroalbuminuria(n = 13)(n = 12)UACR0.7580.0040.6290.032eGFR0.3330.2660.2980.347Moderately reduced renal function (n = 16)(n = 16)(n = 13)UACR0.806<0.0010.7920.001eGFR−0.3520.181−0.4480.124Spearman's rank correlation analysis was performed. Patients with T2DM were stratified into four subgroups according to albuminuria category or renal function: normoalbuminuria (UACR <30 mg/g), microalbuminuria (UACR of 30 to <300 mg/g), macroalbuminuria (UACR ≥300 mg/g), and moderately reduced renal function (eGFR of 30 to <60 mL/min/1.73 m2). DKD, diabetic kidney disease; DPP4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; LPS, lipopolysaccharide; T2DM, type 2 diabetes mellitus; UACR, urinary albumin‐to‐creatinine ratio; ρ, Spearman's correlation coefficient. † Data analyzed using unstimulated monocytes. ‡ Data analyzed using LPS‐stimulated monocytes. Correlation analyses of monocyte DPP4 activity with UACR and eGFR within subgroups stratified by albuminuria and eGFR in patients with T2DM Spearman's rank correlation analysis was performed. Patients with T2DM were stratified into four subgroups according to albuminuria category or renal function: normoalbuminuria (UACR <30 mg/g), microalbuminuria (UACR of 30 to <300 mg/g), macroalbuminuria (UACR ≥300 mg/g), and moderately reduced renal function (eGFR of 30 to <60 mL/min/1.73 m2). DKD, diabetic kidney disease; DPP4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; LPS, lipopolysaccharide; T2DM, type 2 diabetes mellitus; UACR, urinary albumin‐to‐creatinine ratio; ρ, Spearman's correlation coefficient. Data analyzed using unstimulated monocytes. Data analyzed using LPS‐stimulated monocytes. Furthermore, in the T2DM group, we performed univariate and multivariate regression analyses to clarify whether monocyte DPP4 activity is independently associated with urinary albumin excretion, using UACR as a dependent variable. In the univariate analysis, DPP4 activity in unstimulated monocytes was correlated with UACR (standardized β = 1.319, P < 0.001) along with seven items (Table S7), while it was significantly associated with UACR even after adjustment for age and sex (standardized β = 1.266, P < 0.001; Table 4). In the multivariate model 1 adjusted for age and duration of DM, DPP4 activity in unstimulated monocytes was associated with UACR (standardized β = 1.124, P < 0.001; Table 4). Not only in Model 1 but also in Models 2 and 3, DPP4 activity in unstimulated monocytes remained a significant factor after adjustment, suggesting that it was independently associated with higher urinary albumin excretion in patients with T2DM. Table 4Multivariate linear regression models examining the association between DPP4 activity in unstimulated monocytes and UACR in patients with T2DMDependent variables: UACR † Standardized β95% CI P‐valueUnivariate model(Adjusted R 2 = 0.586)DPP4 activity in unstimulated monocytes † 1.3191.041 to 1.597<0.001Age and gender adjusted model(Adjusted R 2 = 0.580)DPP4 activity in unstimulated monocytes † 1.2660.968 to 1.565<0.001Age0.013−0.013 to 0.0380.331Female sex0.076−0.557 to 0.7090.811Multivariate model 1(Adjusted R 2 = 0.636)DPP4 activity in unstimulated monocytes † 1.1240.833 to 1.415<0.001Age0.007−0.017 to 0.0310.545Duration of DM † 1.4490.502 to 2.3950.003Multivariate model 2(Adjusted R 2 = 0.681)DPP4 activity in unstimulated monocytes † 1.0220.735 to 1.308<0.001Age0.008−0.016 to 0.0310.517Duration of DM † 1.3530.463 to 2.2430.004eGFR−0.022−0.036 to −0.0080.003HbA1c † 0.140−1.225 to 1.5050.838Multivariate model 3(Adjusted R 2 = 0.627)DPP4 activity in unstimulated monocytes † 1.1170.821 to 1.413<0.001Age0.007−0.018 to 0.0330.557Duration of DM † 1.4430.484 to 2.4020.004BMI0.017−0.043 to 0.0760.571SBP0.003−0.015 to 0.0210.743A multivariate linear regression analysis with crude and adjusted beta coefficients. AGEs, advanced glycation end products; β, partial regression coefficient; CI, confidence interval; DM, diabetes mellitus; DPP4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; T2DM, type 2 diabetes mellitus; UACR, urinary albumin‐to‐creatinine ratio. † Log‐transformed using the natural logarithm. Multivariate linear regression models examining the association between DPP4 activity in unstimulated monocytes and UACR in patients with T2DM A multivariate linear regression analysis with crude and adjusted beta coefficients. AGEs, advanced glycation end products; β, partial regression coefficient; CI, confidence interval; DM, diabetes mellitus; DPP4, dipeptidyl peptidase‐4; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; T2DM, type 2 diabetes mellitus; UACR, urinary albumin‐to‐creatinine ratio. Log‐transformed using the natural logarithm. Finally, to assess the role of monocyte DPP4 in inflammation, we analyzed inflammatory markers after co‐treatment with LPS and vildagliptin. In cultured monocytes from both the T2DM and control groups, LPS increased IL‐1β, IL‐6, MCP‐1, and TNFA gene expression, partially suppressed by vildagliptin; similarly, TNF‐α levels in culture supernatants rose with LPS and decreased with vildagliptin (Figures 3 and S4), suggesting that LPS‐stimulated inflammatory responses are partly mediated by DPP4. Analysis of the effects of LPS and vildagliptin on the expression of pro‐inflammatory genes and TNF‐α production in cultured monocytes from the T2DM group. Cultured monocytes from the T2DM group were treated with LPS at a concentration of 10 ng/mL for 4 h, with or without a pretreatment of vildagliptin at a concentration of 10 μM for 2 h. Quantitative analyses of gene expression levels of (a) IL‐1β, (b) IL‐6, (c) MCP‐1, and (d) TNFA, along with (e) TNF‐α levels in the culture supernatants, are shown (n = 50). Data were analyzed using the Wilcoxon signed‐rank test. All data are presented as box‐and‐whisker plots. The box represents the interquartile range, the horizontal line within the box indicates the median, and the whiskers represent the 10th and 90th percentiles. The median values are indicated at the bottom of each panel. ACTB, Actin beta; DPP4, dipeptidyl peptidase‐4; IL‐1β, interleukin 1 beta; IL‐6, interleukin‐6; LPS, lipopolysaccharide; MCP‐1, monocyte chemotactic protein‐1; T2DM, type 2 diabetes mellitus; TNFA, tumor necrosis factor‐alpha. ***P < 0.001. DISCUSSION We examined whether the characteristics of DPP4 in monocytes of patients with T2DM are associated with DKD pathophysiology using human peripheral blood monocytes. The results suggested that monocyte DPP4 activity in patients with T2DM is higher than that in healthy controls, and it is related to albuminuria, with or without LPS stimulation. In this study, monocyte DPP4 activity in patients with T2DM correlated with UACR, but not with eGFR. This finding may reflect both the biological role of DPP4 and the distinct pathophysiological information provided by renal markers 31 . DPP4 acts as an immunomodulatory molecule on monocytes, and increased activity may indicate an activated inflammatory phenotype 32 , 33 . Such inflammation contributes to glomerular injury and albuminuria in DKD 34 , 35 . In contrast, eGFR reflects global renal function and may remain preserved in early‐stage DKD due to hyperfiltration or limited nephron loss 36 . Accordingly, albuminuria and eGFR decline are increasingly recognized as complementary but not necessarily parallel manifestations of DKD 31 , 37 . Taken together, increased monocyte DPP4 activity may be more closely linked to inflammatory glomerular injury leading to increased urinary albumin excretion than to the reduction in global filtration function detected by eGFR. Monocyte/macrophage infiltration plays a key role in DKD pathogenesis by promoting renal inflammation and structural injury 15 , 38 , 39 , 40 . Suppression of this recruitment has shown renoprotective effects in animal models 41 , 42 , 43 . Consistent with previous reports 16 , 17 , 18 , we found that LPS‐stimulated pro‐inflammatory gene expression in monocytes positively correlated with urinary albumin excretion. DPP4 promotes DKD progression via inflammatory pathways, as shown in experimental models 22 , 44 ; however, its role in monocytes in relation to DKD remains unclear. Previous studies have suggested that DPP4 and inflammation are interrelated in monocytes/macrophages. LPS upregulates DPP4 via Toll‐like receptor 4 (TLR4) in monocytes/macrophages, while soluble DPP4 enhances pro‐inflammatory gene expression, which is abolished by DPP4 inhibition 23 , 24 , 45 . Similarly, in our study, DPP4 inhibitors partially suppressed LPS‐stimulated inflammatory responses in monocytes. Additionally, monocyte DPP4 expression reportedly correlates with atherosclerosis severity and may promote it via inflammation 46 . In our context, inflammatory pathways may play a mediating role in the relationship between monocyte DPP4 and DKD. In this study, LPS stimulation was used to assess monocyte DPP4 under resting and inflammatory conditions. Unstimulated monocytes have low inflammatory expression, limiting detection of differences 47 , 48 , whereas LPS robustly induces cytokines 47 , 49 ; thus, it is widely used to evaluate inflammatory responsiveness 48 . Based on this rationale, we hypothesized that LPS‐stimulated conditions would provide a functionally relevant model for investigating inflammation‐related mechanisms in DKD. In our analysis, pro‐inflammatory gene expression in unstimulated monocytes from the T2DM group was not correlated with hsCRP and AGEs, markers of low‐grade inflammation. However, monocyte DPP4 activity in patients with T2DM was significantly associated with pro‐inflammatory gene expression, hsCRP, AGEs, and UACR under both unstimulated and LPS‐stimulated conditions. These findings suggest that, at least in our experimental system, monocyte DPP4 activity reflects not only inducible inflammatory responsiveness but also a basal inflammatory state. This is consistent with DKD pathophysiology, in which chronic low‐grade inflammation and monocyte/macrophage activation play central roles 34 . This study had five main limitations. First, the small number of patients with T2DM in this study prevented the simultaneous entry of all items known to be risk factors for albuminuria and renal impairment, such as age, sex, BMI, SBP, and HbA1c, into the multivariate analysis, potentially weakening the statistical power of the findings. Similarly, limited subgroup sizes after stratification by albuminuria and eGFR precluded multivariable analyses within each subgroup; thus, subgroup findings should be interpreted with caution. The only prior study examining DPP4 expression in human peripheral blood monocytes 46 included 27 patients with arteriosclerosis, whereas our study involved a larger cohort of 64 patients with T2DM. Nevertheless, future studies with larger cohorts are warranted. Second, although the T2DM cohort included patients with macroalbuminuria and moderately reduced eGFR, most had early‐stage renal complications. Exclusion of patients taking incretin‐based medications may have limited recruitment of advanced DKD cases, where such therapies are more commonly used 50 . Therefore, while we found that monocyte DPP4 activity was associated with UACR across subgroups stratified by albuminuria and renal function, our findings may primarily reflect associations in patients with earlier‐stage renal involvement and may not be fully generalizable to more advanced disease. Third, we investigated DPP4 gene expression and DPP4 activity in monocytes; however, flow cytometry analysis of DPP4 expression was not conducted. Fourth, protein‐level validation of inflammation‐related markers was not performed due to limited monocyte yield and prioritization of RNA and DPP4 activity assays. Supernatant‐based experiments strengthened an association between DPP4 and inflammation, but further studies are needed. Finally, the results of this cross‐sectional study do not establish whether DPP4 in monocytes directly contributes to increased urinary albumin excretion or renal injury, warranting further mechanistic studies. In conclusion, our findings indicate that the characteristics of DPP4 in peripheral blood monocytes are associated with urinary albumin excretion in patients with T2DM. Monocytes may serve as a cellular link between DPP4 and DKD. Disclosure The authors declare no conflict of interest. Approval of the research protocol: The study protocol was approved by the certified review boards of the University of Yamanashi and Isawa Hot Spring Hospital. Informed consent: Written informed consent was obtained from all participants. The participants were allowed to refuse to participate. Approval date of registry and the registration no. of the study/trial: Approval date of registry by the certified review board of the University of Yamanashi, March 17, 2017, and approval number 1668. Approval date of registry by the certified review board of Isawa Hot Spring Hospital, February 7, 2018, and approval number 2018‐003. Animal studies: N/A. Supporting information Figure S1 Analysis of DPP4 gene expression in cultured human monocytes. (a) Comparison of DPP4 gene expression in unstimulated monocytes between T2DM and healthy control groups (T2DM, n = 64; controls, n = 50). Data were compared using the Mann–Whitney U test. (b) The effects of LPS and vildagliptin on monocyte DPP4 gene expression. Cultured monocytes in the T2DM group were treated with LPS at a concentration of 10 ng/mL for 4 h, with or without a pretreatment of vildagliptin at a concentration of 10 μM for 2 h. The quantitative analysis of DPP4 gene expression (n = 50) is shown. Data were analyzed using the Wilcoxon signed‐rank test. ACTB, actin beta; DPP4, dipeptidyl peptidase‐4; LPS, lipopolysaccharide; mRNA, messenger ribonucleic acid; T2DM, type 2 diabetes mellitus. ***P < 0.001. Figure S2 Analysis of the effects of LPS and vildagliptin on monocyte DPP4 gene expression in healthy controls. Cultured monocytes in healthy controls were treated with LPS at a concentration of 10 ng/mL for 4 h, with or without a pretreatment of vildagliptin at a concentration of 10 μM for 2 h. The quantitative analysis of DPP4 gene expression (n = 48) is shown. Data were analyzed using the Wilcoxon signed‐rank test. ACTB, actin beta; DPP4, dipeptidyl peptidase‐4; LPS, lipopolysaccharide; mRNA, messenger ribonucleic acid; T2DM, type 2 diabetes mellitus. ***P < 0.001. Figure S3 Analysis of the effects of LPS and vildagliptin on monocyte DPP4 activity in healthy controls. Cultured monocytes in healthy controls were treated with LPS at a concentration of 10 ng/mL for 4 h, with or without a pretreatment of vildagliptin at a concentration of 10 μM for 2 h. The quantitative analysis of DPP4 activity (n = 48) is shown. Data were analyzed using the Wilcoxon signed‐rank test. DPP4, dipeptidyl peptidase‐4; LPS, lipopolysaccharide; T2DM, type 2 diabetes mellitus. ***P < 0.001. Figure S4 Analysis of the effects of LPS and vildagliptin on the expression of pro‐inflammatory genes and TNF‐α production in cultured monocytes from the healthy control group. Cultured monocytes from control group were treated with LPS at a concentration of 10 ng/mL for 4 h, with or without a pretreatment of vildagliptin at a concentration of 10 μM for 2 h. Quantitative analyses of gene expression levels of (a) IL‐1β, (b) IL‐6, (c) MCP‐1, and (d) TNFA, along with (e) TNF‐α concentrations in the culture supernatants, are shown (n = 48). Data were analyzed using the Wilcoxon signed‐rank test. All data are presented as box‐and‐whisker plots. The box represents the interquartile range, the horizontal line within the box indicates the median, and the whiskers represent the 10th and 90th percentiles. The median values are indicated at the bottom of each panel. ACTB, actin beta; DPP4, dipeptidyl peptidase‐4; IL‐1β, interleukin 1 beta; IL‐6, interleukin‐6; LPS, lipopolysaccharide; MCP‐1, monocyte chemotactic protein‐1; TNFA, tumor necrosis factor‐alpha. ***P < 0.001. Table S1 Correlation analysis between plasma DPP4 activity, UACR, eGFR, and other clinical characteristics in patients with T2DM. Table S2 Correlation analysis between plasma DPP4 activity and other clinical characteristics in healthy controls. Table S3 Correlation analyses of hsCRP, AGEs, and inflammatory markers in monocytes in patients with T2DM. Table S4 Correlation analysis between DPP4 gene expression in cultured monocytes and other clinical characteristics in patients with T2DM. Table S5 Correlation analysis between DPP4 gene expression in cultured monocytes and other clinical characteristics in healthy controls. Table S6 Correlation analysis between DPP4 activity in cultured monocytes and other clinical characteristics in the healthy controls. Table S7 Univariate linear regression models examining the association between UACR and other clinical characteristics in patients with T2DM. Acknowledgments This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Number JP25K21120) and Young Researcher Grants (2021) from The Japan Diabetes Society. We would like to thank Dr. Asako Miyazaki for her assistance in the collection of samples from healthy controls. Contributor Information Hideyuki Okuma, Email: hokuma@yamanashi.ac.jp. Kyoichiro Tsuchiya, Email: tsuchiyak@yamanashi.ac.jp. DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Figure S1 Analysis of DPP4 gene expression in cultured human monocytes. (a) Comparison of DPP4 gene expression in unstimulated monocytes between T2DM and healthy control groups (T2DM, n = 64; controls, n = 50). Data were compared using the Mann–Whitney U test. (b) The effects of LPS and vildagliptin on monocyte DPP4 gene expression. Cultured monocytes in the T2DM group were treated with LPS at a concentration of 10 ng/mL for 4 h, with or without a pretreatment of vildagliptin at a concentration of 10 μM for 2 h. The quantitative analysis of DPP4 gene expression (n = 50) is shown. Data were analyzed using the Wilcoxon signed‐rank test. ACTB, actin beta; DPP4, dipeptidyl peptidase‐4; LPS, lipopolysaccharide; mRNA, messenger ribonucleic acid; T2DM, type 2 diabetes mellitus. ***P < 0.001. Figure S2 Analysis of the effects of LPS and vildagliptin on monocyte DPP4 gene expression in healthy controls. Cultured monocytes in healthy controls were treated with LPS at a concentration of 10 ng/mL for 4 h, with or without a pretreatment of vildagliptin at a concentration of 10 μM for 2 h. The quantitative analysis of DPP4 gene expression (n = 48) is shown. Data were analyzed using the Wilcoxon signed‐rank test. ACTB, actin beta; DPP4, dipeptidyl peptidase‐4; LPS, lipopolysaccharide; mRNA, messenger ribonucleic acid; T2DM, type 2 diabetes mellitus. ***P < 0.001. Figure S3 Analysis of the effects of LPS and vildagliptin on monocyte DPP4 activity in healthy controls. Cultured monocytes in healthy controls were treated with LPS at a concentration of 10 ng/mL for 4 h, with or without a pretreatment of vildagliptin at a concentration of 10 μM for 2 h. The quantitative analysis of DPP4 activity (n = 48) is shown. Data were analyzed using the Wilcoxon signed‐rank test. DPP4, dipeptidyl peptidase‐4; LPS, lipopolysaccharide; T2DM, type 2 diabetes mellitus. ***P < 0.001. Figure S4 Analysis of the effects of LPS and vildagliptin on the expression of pro‐inflammatory genes and TNF‐α production in cultured monocytes from the healthy control group. Cultured monocytes from control group were treated with LPS at a concentration of 10 ng/mL for 4 h, with or without a pretreatment of vildagliptin at a concentration of 10 μM for 2 h. Quantitative analyses of gene expression levels of (a) IL‐1β, (b) IL‐6, (c) MCP‐1, and (d) TNFA, along with (e) TNF‐α concentrations in the culture supernatants, are shown (n = 48). Data were analyzed using the Wilcoxon signed‐rank test. All data are presented as box‐and‐whisker plots. The box represents the interquartile range, the horizontal line within the box indicates the median, and the whiskers represent the 10th and 90th percentiles. The median values are indicated at the bottom of each panel. ACTB, actin beta; DPP4, dipeptidyl peptidase‐4; IL‐1β, interleukin 1 beta; IL‐6, interleukin‐6; LPS, lipopolysaccharide; MCP‐1, monocyte chemotactic protein‐1; TNFA, tumor necrosis factor‐alpha. ***P < 0.001. Table S1 Correlation analysis between plasma DPP4 activity, UACR, eGFR, and other clinical characteristics in patients with T2DM. Table S2 Correlation analysis between plasma DPP4 activity and other clinical characteristics in healthy controls. Table S3 Correlation analyses of hsCRP, AGEs, and inflammatory markers in monocytes in patients with T2DM. Table S4 Correlation analysis between DPP4 gene expression in cultured monocytes and other clinical characteristics in patients with T2DM. Table S5 Correlation analysis between DPP4 gene expression in cultured monocytes and other clinical characteristics in healthy controls. Table S6 Correlation analysis between DPP4 activity in cultured monocytes and other clinical characteristics in the healthy controls. Table S7 Univariate linear regression models examining the association between UACR and other clinical characteristics in patients with T2DM. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.